^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Non Small Cell Lung Cancer
    Drug:Tyvyt (sintilimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2021
    Title:

    Sintilimab Plus Docetaxel in Previously Treated Advanced NSCLC, Updates on Progression - Free and Overall Survival

    Published date:
    08/18/2021
    Excerpt:
    ...receive docetaxel (75mg/m2, day 1) plus sintilimab (200mg, day 3) every 3 weeks for 4-6 cycles...Median DOR was 6.46 months (95% 1.28, NA). Median TTR (Time to Response) was 3.89 months (95% 1.61, 4.99)….the first study of a PD-1 inhibitor plus chemotherapy in advanced Chinese NSCLC patients who had failed first-line standard therapy. The encouraging efficacy and tolerable safety profile suggest a potential role of this combination in second-line setting.
    Secondary therapy:
    docetaxel
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Asia 2020
    Title:

    402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) (ID 567)

    Published date:
    11/17/2020
    Excerpt:
    Eligible pts would receive docetaxel (75mg/m2, day 1) plus sintilimab (200mg, day 3)...Estimated median PFS was 5.5m (95%CI 3.6-NE)...Of the 25 evaluable pts, ORR is 24% (95%CI 9%, 45%), DCR is 92% (95%CI 74%, 99%)...EGFR/ALK positive pts….advanced Chinese NSCLC pts...
    Secondary therapy:
    docetaxel